Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk. Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use. Findings During prospective follow-up, 12 110 postmenopausal women, 5...
Background Menarche and menopause mark the onset and cessation, respectively, of ovarian activity as...
Background: Published findings on breast cancer risk associated with different types of menopausal h...
BACKGROUND: Ovarian cancer is the fourth most common cancer in women in the UK, with about 6700 deve...
Background Half the epidemiological studies with information about menopausal hormone therapy and ov...
Background Half the epidemiological studies with information about menopausal hormone therapy and ov...
BACKGROUND: Half the epidemiological studies with information about menopausal hormone therapy and o...
Background Half the epidemiological studies with information about menopausal hormone therapy and ov...
Knowledge about the impact of menopausal hormone therapy (MHT) on the risk of ovarian cancer (OvC) i...
The association between menopausal hormone therapy (HT) and risk of ovarian cancer was assessed amon...
Objective: The objective of this study was to determine if use of menopausal hormones was associated...
PurposePrior studies of menopausal hormone therapy (MHT) and ovarian cancer survival have been limit...
BackgroundMenarche and menopause mark the onset and cessation, respectively, of ovarian activity ass...
Background Menarche and menopause mark the onset and cessation, respectively, of ovarian activity as...
SummaryBackgroundMenarche and menopause mark the onset and cessation, respectively, of ovarian activ...
Background: Although menopausal hormone therapy (MHT) use has been linked with an increased risk of ...
Background Menarche and menopause mark the onset and cessation, respectively, of ovarian activity as...
Background: Published findings on breast cancer risk associated with different types of menopausal h...
BACKGROUND: Ovarian cancer is the fourth most common cancer in women in the UK, with about 6700 deve...
Background Half the epidemiological studies with information about menopausal hormone therapy and ov...
Background Half the epidemiological studies with information about menopausal hormone therapy and ov...
BACKGROUND: Half the epidemiological studies with information about menopausal hormone therapy and o...
Background Half the epidemiological studies with information about menopausal hormone therapy and ov...
Knowledge about the impact of menopausal hormone therapy (MHT) on the risk of ovarian cancer (OvC) i...
The association between menopausal hormone therapy (HT) and risk of ovarian cancer was assessed amon...
Objective: The objective of this study was to determine if use of menopausal hormones was associated...
PurposePrior studies of menopausal hormone therapy (MHT) and ovarian cancer survival have been limit...
BackgroundMenarche and menopause mark the onset and cessation, respectively, of ovarian activity ass...
Background Menarche and menopause mark the onset and cessation, respectively, of ovarian activity as...
SummaryBackgroundMenarche and menopause mark the onset and cessation, respectively, of ovarian activ...
Background: Although menopausal hormone therapy (MHT) use has been linked with an increased risk of ...
Background Menarche and menopause mark the onset and cessation, respectively, of ovarian activity as...
Background: Published findings on breast cancer risk associated with different types of menopausal h...
BACKGROUND: Ovarian cancer is the fourth most common cancer in women in the UK, with about 6700 deve...